Page last updated: 2024-10-22

amantadine and Fatigue

amantadine has been researched along with Fatigue in 54 studies

amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source

Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.

Research Excerpts

ExcerptRelevanceReference
"Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting."9.41Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021)
"The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS."9.27Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018)
"One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS."9.17Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013)
"The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)."9.16Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012)
"We investigated the effect of amantadine on cognitive processing in patients with multiple sclerosis (MS) and fatigue with objective electrophysiological measures."9.09Amantadine influences cognitive processing in patients with multiple sclerosis. ( Hauser, U; Heinze, HJ; Sailer, M; Schoenfeld, MA; Smid, HG, 2000)
"Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS."9.08The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996)
"Because amantadine has been shown to reduce fatigue in patients with multiple sclerosis, we performed a double-blind, placebo-controlled study to assess its efficacy in the disabling symptom of post-polio fatigue."9.08A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. ( Dalakas, MC; Dambrosia, JM; Stein, DP, 1995)
"To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue."9.08Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995)
"In a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six."9.06Amantadine, fatigue, and multiple sclerosis. ( Appenzeller, O; Rosenberg, GA, 1988)
"We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo."9.05Amantadine therapy for fatigue in multiple sclerosis. ( Murray, TJ, 1985)
"To determine the effectiveness and safety of amantadine in treating fatigue in people with MS."8.84Amantadine for fatigue in multiple sclerosis. ( Branãs, P; D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2007)
"Randomised, placebo or other drugs-controlled, double-blind trials of amantadine in MS people with fatigue."8.82Amantadine for fatigue in multiple sclerosis. ( D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2003)
"Amantadine is sometimes used to treat fatigue in multiple sclerosis."8.02Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021)
"Acupuncture appears to be associated with benefits for a proportion of patients with fatigue who are resistant to conventional drugs such as amantadine, and this finding justifies further research."7.79Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. ( Bahrami Taghanaki, HR; Foroughipour, M; Khazaei, M; Saeidi, M; Sasannezhad, P; Shoeibi, A, 2013)
"Changes in modified fatigue impact scale (MFIS) score and network RS FC were assessed."7.01Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. ( Colombo, B; Filippi, M; Martinelli, V; Rocca, MA; Valsasina, P, 2021)
"Amantadine was not superior to placebo."6.72Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006)
"Fatigue is a common symptom of multiple sclerosis (MS) that is without an effective treatment."6.66Amantadine treatment of fatigue associated with multiple sclerosis. ( Cohen, RA; Fisher, M, 1989)
"The present research was intended to investigate the effectiveness of acupuncture plus amantadine compared with amantadine alone on fatigue in patients with relapsing-remitting MS (RRMS) in the remission stage of the disease."5.69Effectiveness of acupuncture for fatigue in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial. ( Kazemi, AH; Khodaie, F; Naser Moghadasi, A; Zhao, B, 2023)
"Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting."5.41Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021)
"The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS."5.27Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018)
"One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS."5.17Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013)
"The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)."5.16Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012)
"We investigated the effect of amantadine on cognitive processing in patients with multiple sclerosis (MS) and fatigue with objective electrophysiological measures."5.09Amantadine influences cognitive processing in patients with multiple sclerosis. ( Hauser, U; Heinze, HJ; Sailer, M; Schoenfeld, MA; Smid, HG, 2000)
"Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS."5.08The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996)
"To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue."5.08Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995)
"Because amantadine has been shown to reduce fatigue in patients with multiple sclerosis, we performed a double-blind, placebo-controlled study to assess its efficacy in the disabling symptom of post-polio fatigue."5.08A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. ( Dalakas, MC; Dambrosia, JM; Stein, DP, 1995)
"In a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six."5.06Amantadine, fatigue, and multiple sclerosis. ( Appenzeller, O; Rosenberg, GA, 1988)
"We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo."5.05Amantadine therapy for fatigue in multiple sclerosis. ( Murray, TJ, 1985)
"Current limited data suggest that amantadine may be the only drug that has relatively sufficient evidences in treatment of fatigue symptoms in MS."4.95Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. ( Deng, XY; Wang, L; Yang, TT; Yu, G, 2017)
" We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis."4.91Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015)
" The effects of amantadine from one randomised, double-blind, placebo-controlled, cross-over trial comparing amantadine with placebo for the treatment of fatigue in 80 people with Guillain-Barré syndrome (GBS) were uncertain for the proportion of people achieving a favourable outcome six weeks post-intervention (odds ratio (OR) 0."4.90Interventions for fatigue in peripheral neuropathy. ( Garssen, MP; Stockley, RC; van Doorn, PA; White, CM, 2014)
" In the completed study, adult patients with relapsing-remitting and secondary progressive MS were exposed to both acetyl L-carnitine 2 grams daily and amantadine 200 mg daily The effects of carnitine on fatigue are unclear."4.88Carnitine for fatigue in multiple sclerosis. ( Nathwani, S; Rowell, G; Spiwak, R; Tejani, AM; Wasdell, M, 2012)
" Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis."4.86Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010)
"To determine the effectiveness and safety of amantadine in treating fatigue in people with MS."4.84Amantadine for fatigue in multiple sclerosis. ( Branãs, P; D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2007)
"Randomised, placebo or other drugs-controlled, double-blind trials of amantadine in MS people with fatigue."4.82Amantadine for fatigue in multiple sclerosis. ( D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2003)
" Only amantadine appears to have some proven ability to alleviate the fatigue in MS, though only a proportion of users will obtain benefit and then only some of these patients will benefit sufficiently to take the drug in the long term."4.80Treatments for fatigue in multiple sclerosis: a rapid and systematic review. ( Brañas, P; Burls, A; Fry-Smith, A; Hyde, C; Jordan, R, 2000)
"Amantadine is sometimes used to treat fatigue in multiple sclerosis."4.02Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021)
"Acupuncture appears to be associated with benefits for a proportion of patients with fatigue who are resistant to conventional drugs such as amantadine, and this finding justifies further research."3.79Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. ( Bahrami Taghanaki, HR; Foroughipour, M; Khazaei, M; Saeidi, M; Sasannezhad, P; Shoeibi, A, 2013)
"Changes in modified fatigue impact scale (MFIS) score and network RS FC were assessed."3.01Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. ( Colombo, B; Filippi, M; Martinelli, V; Rocca, MA; Valsasina, P, 2021)
"Amantadine was not superior to placebo."2.72Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006)
"Fatigue is a common symptom of multiple sclerosis (MS) that is without an effective treatment."2.66Amantadine treatment of fatigue associated with multiple sclerosis. ( Cohen, RA; Fisher, M, 1989)
"Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions."2.48Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012)
"Fatigue is recognized as one of the most disabling and common symptoms of MS."2.44Treating fatigue. ( Hum, S; Lapierre, Y, 2007)
"Modafinil has been shown to be effective in some studies, and amantadine is an alternative for patients who do not respond to or cannot tolerate modafinil."2.42Management of fatigue in patients with multiple sclerosis. ( Zifko, UA, 2004)
"Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1."2.41Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001)
"Fatigue is a common symptom in patients with multiple sclerosis."2.40['Fatigue' in multiple sclerosis]. ( Hohlfeld, R; Zimmermann, C, 1999)
"Multiple sclerosis is a demyelinating disorder of the central nervous system characterized by exacerbations and remissions of symptoms."2.38Update on multiple sclerosis therapy. ( Mitchell, G, 1993)
"The Fatigue Impact Scale for Daily Use (D-FIS) is an eight-item instrument designed to measure subjective daily experience of fatigue."1.34Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). ( Antigüedad, AR; Benito-León, J; de Andrés, C; Frades, B; Huete-Antón, B; Martínez-Ginés, ML; Martínez-Martín, P; Meca-Lallana, JE; Rodríguez-García, E; Ruiz-Martínez, J, 2007)
"The term "fatigue" has been used for asthenia at rest but also for fatigability during exercise."1.31[Therapeutic indications for managing symptoms: fatigue]. ( Waubant, E, 2001)

Research

Studies (54)

TimeframeStudies, this research(%)All Research%
pre-19905 (9.26)18.7374
1990's11 (20.37)18.2507
2000's16 (29.63)29.6817
2010's13 (24.07)24.3611
2020's9 (16.67)2.80

Authors

AuthorsStudies
Nourbakhsh, B3
Bradley, L1
Khodaie, F1
Naser Moghadasi, A1
Kazemi, AH1
Zhao, B1
Rocca, MA2
Valsasina, P2
Lamanna, MT1
Colombo, B2
Martinelli, V2
Filippi, M2
Perez, DQ1
Espiritu, AI1
Jamora, RDG1
Revirajan, N2
Morris, B1
Cordano, C1
Creasman, J1
Manguinao, M1
Krysko, K1
Rutatangwa, A1
Auvray, C1
Aljarallah, S1
Jin, C1
Mowry, E1
McCulloch, C1
Waubant, E3
Bourdette, D1
Grieb, P1
Świątkiewicz, M1
Prus, K1
Rejdak, K1
Yang, TT1
Wang, L1
Deng, XY1
Yu, G1
Ledinek, AH1
Sajko, MC1
Rot, U1
Hamonet, C1
Césaro, P1
White, CM1
van Doorn, PA2
Garssen, MP2
Stockley, RC1
Mücke, M1
Cuhls, H1
Peuckmann-Post, V1
Minton, O1
Stone, P1
Radbruch, L2
Santarnecchi, E1
Rossi, S1
Bartalini, S1
Cincotta, M1
Giovannelli, F1
Tatti, E1
Ulivelli, M1
Peuckmann, V1
Elsner, F1
Krumm, N1
Trottenberg, P1
Kirshbaum, M1
Tejani, AM1
Wasdell, M1
Spiwak, R1
Rowell, G1
Nathwani, S1
Induruwa, I1
Constantinescu, CS1
Gran, B1
Shaygannejad, V1
Janghorbani, M1
Ashtari, F1
Zakeri, H1
Foroughipour, M1
Bahrami Taghanaki, HR1
Saeidi, M1
Khazaei, M1
Sasannezhad, P1
Shoeibi, A1
Taus, C2
Giuliani, G2
Pucci, E2
D'Amico, R2
Solari, A2
Bakshi, R1
Iwasaki, Y1
Iguchi, H1
Ichikawa, Y1
Igarashi, O1
Kawabe, S1
Kiyozuka, T1
Maruyama, M1
Ikeda, K1
Fujioka, T1
Tomassini, V1
Pozzilli, C1
Onesti, E1
Pasqualetti, P1
Marinelli, F1
Pisani, A1
Fieschi, C1
Zifko, UA1
Schwid, SR1
Murray, TJ2
Schmitz, PI1
Merkies, IS1
Jacobs, BC1
van der Meché, FG1
Debouverie, M1
Pittion, S1
Boërio, D1
Lefaucheur, JP1
Hogrel, JY1
Créange, A1
Branãs, P2
Benito-León, J1
Martínez-Martín, P1
Frades, B1
Martínez-Ginés, ML1
de Andrés, C1
Meca-Lallana, JE1
Antigüedad, AR1
Huete-Antón, B1
Rodríguez-García, E1
Ruiz-Martínez, J1
Lapierre, Y1
Hum, S1
Krupp, LB3
Coyle, PK2
Doscher, C2
Miller, A1
Cross, AH1
Jandorf, L1
Halper, J1
Johnson, B1
Morgante, L1
Grimson, R1
Stein, DP1
Dambrosia, JM1
Dalakas, MC1
Mitchell, G1
Geisler, MW1
Sliwinski, M1
Masur, DM1
Poser, CM1
Dulli, D1
Schutta, H1
Huete, B1
Varona, L1
Zimmermann, C1
Hohlfeld, R1
Sailer, M1
Heinze, HJ1
Schoenfeld, MA1
Hauser, U1
Smid, HG1
Jordan, R1
Fry-Smith, A1
Burls, A1
Hyde, C1
Christodoulou, C1
Chiba, S1
Ito, M1
Matsumoto, H1
Wiggs, JW1
Dunn, MG1
Cohen, RA1
Fisher, M1
Rosenberg, GA1
Appenzeller, O1
Potvin, AR1
Albers, JW1
Repa, BS1
Henderson, WG1
Walker, JE1
Stribley, RF1
Tourtellotte, WW1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis[NCT03185065]Phase 3141 participants (Actual)Interventional2017-10-04Completed
A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162]Early Phase 120 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093]40 participants (Anticipated)Observational2022-04-30Not yet recruiting
Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924]42 participants (Anticipated)Interventional2020-08-01Recruiting
Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020]100 participants (Anticipated)Interventional2015-12-31Recruiting
Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820]105 participants (Actual)Interventional2017-05-31Completed
A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525]Phase 359 participants (Actual)Interventional2010-06-30Completed
Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea[NCT01563900]0 participants (Actual)Interventional2012-02-29Withdrawn (stopped due to Was unable to recruit subjects)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Acceptability of Treatment as Assessed by a Single Question Questionnaire

"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period

InterventionParticipants (Count of Participants)
Placebo39
Amantadine41
Modafinil55
Methylphenidate55

Epworth Sleepiness Scale (ESS) Score

ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period

Interventionscore on a scale (Least Squares Mean)
Placebo9.4
Amantadine9.3
Modafinil8.3
Methylphenidate8.8

Modified Fatigue Impact Scale (MFIS) Score

MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period

Interventionscore on a scale (Least Squares Mean)
Placebo40.6
Amantadine41.3
Modafinil39.0
Methylphenidate38.6

Quality of Life in Neurological Disorders (Neuro-QoL) Item Bank - Fatigue Score

Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period

Interventionscore on a scale (Least Squares Mean)
Placebo53.1
Amantadine53.0
Modafinil52.5
Methylphenidate52.0

Reviews

19 reviews available for amantadine and Fatigue

ArticleYear
Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis.
    Neurodegenerative disease management, 2020, Volume: 10, Issue:6

    Topics: Amantadine; Fatigue; Female; Humans; Male; Multiple Sclerosis

2020
Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
    Journal of the neurological sciences, 2017, Sep-15, Volume: 380

    Topics: 4-Aminopyridine; Amantadine; Central Nervous System Stimulants; Dopamine Agents; Drug Therapy; Fatig

2017
Interventions for fatigue in peripheral neuropathy.
    The Cochrane database of systematic reviews, 2014, Dec-18, Issue:12

    Topics: Adult; Amantadine; Ascorbic Acid; Charcot-Marie-Tooth Disease; Child; Fatigue; Guillain-Barre Syndro

2014
Pharmacological treatments for fatigue associated with palliative care.
    The Cochrane database of systematic reviews, 2015, May-30, Issue:5

    Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea

2015
Pharmacological treatments for fatigue associated with palliative care.
    The Cochrane database of systematic reviews, 2010, Nov-10, Issue:11

    Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney

2010
Pharmacologic treatments for fatigue associated with palliative care.
    Clinical journal of oncology nursing, 2011, Volume: 15, Issue:4

    Topics: Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Evidence-Based Medicine; Fatigu

2011
Carnitine for fatigue in multiple sclerosis.
    The Cochrane database of systematic reviews, 2012, May-16, Issue:5

    Topics: Acetylcarnitine; Adult; Amantadine; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trial

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Fatigue in multiple sclerosis - a brief review.
    Journal of the neurological sciences, 2012, Dec-15, Volume: 323, Issue:1-2

    Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The

2012
Amantadine for fatigue in multiple sclerosis.
    The Cochrane database of systematic reviews, 2003, Issue:2

    Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Dopamine Agents; Fatigue; Humans; Multiple Scleros

2003
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2003, Volume: 9, Issue:3

    Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple

2003
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2003, Volume: 9, Issue:3

    Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple

2003
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2003, Volume: 9, Issue:3

    Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple

2003
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2003, Volume: 9, Issue:3

    Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple

2003
Management of fatigue in patients with multiple sclerosis.
    Drugs, 2004, Volume: 64, Issue:12

    Topics: Amantadine; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Clinical

2004
[Pathophysiology and treatment of fatigue in multiple sclerosis].
    Revue neurologique, 2006, Volume: 162, Issue:3

    Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N

2006
Amantadine for fatigue in multiple sclerosis.
    The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1

    Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Dopamine Agents; Fatigue; Humans; Multiple Scleros

2007
Treating fatigue.
    International MS journal, 2007, Volume: 14, Issue:2

    Topics: Amantadine; Central Nervous System Stimulants; Comorbidity; Diagnosis, Differential; Dopamine Agents

2007
Update on multiple sclerosis therapy.
    The Medical clinics of North America, 1993, Volume: 77, Issue:1

    Topics: Amantadine; Baclofen; Fatigue; Humans; Immunosuppression Therapy; Interferons; Multiple Sclerosis; M

1993
['Fatigue' in multiple sclerosis].
    Der Nervenarzt, 1999, Volume: 70, Issue:6

    Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis;

1999
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
    Health technology assessment (Winchester, England), 2000, Volume: 4, Issue:27

    Topics: Amantadine; Central Nervous System Stimulants; Cost-Benefit Analysis; Dopamine Agents; Evidence-Base

2000
Fatigue in multiple sclerosis.
    Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3

    Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste

2001
Quantitative evaluation of neuropharmacological trials.
    Clinical pharmacology and therapeutics, 1974, Volume: 15, Issue:3

    Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin

1974

Trials

18 trials available for amantadine and Fatigue

ArticleYear
Effectiveness of acupuncture for fatigue in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial.
    Acupuncture in medicine : journal of the British Medical Acupuncture Society, 2023, Volume: 41, Issue:4

    Topics: Acupuncture Therapy; Amantadine; Fatigue; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-

2023
Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
    Journal of neurology, 2023, Volume: 270, Issue:10

    Topics: Amantadine; Brain; Brain Mapping; Dopamine; Fatigue; Humans; Magnetic Resonance Imaging; Multiple Sc

2023
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
    The Lancet. Neurology, 2021, Volume: 20, Issue:1

    Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug

2021
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
    The Lancet. Neurology, 2021, Volume: 20, Issue:1

    Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug

2021
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
    The Lancet. Neurology, 2021, Volume: 20, Issue:1

    Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug

2021
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
    The Lancet. Neurology, 2021, Volume: 20, Issue:1

    Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug

2021
Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine.
    European journal of neurology, 2021, Volume: 28, Issue:7

    Topics: 4-Aminopyridine; Amantadine; Brain; Fatigue; Humans; Magnetic Resonance Imaging; Multiple Sclerosis

2021
Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial.
    Contemporary clinical trials, 2018, Volume: 64

    Topics: Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Fatigue; Hum

2018
Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study.
    Clinical neurology and neurosurgery, 2013, Volume: 115 Suppl 1

    Topics: Acetylcarnitine; Adult; Amantadine; Benzhydryl Compounds; Drug Combinations; Fatigue; Female; Humans

2013
Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study.
    Neurological research, 2012, Volume: 34, Issue:9

    Topics: Adult; Amantadine; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross

2012
Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.
    Journal of the neurological sciences, 2004, Mar-15, Volume: 218, Issue:1-2

    Topics: Acetylcarnitine; Adult; Amantadine; Analgesics, Non-Narcotic; Analysis of Variance; Confidence Inter

2004
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.
    Journal of neurology, neurosurgery, and psychiatry, 2006, Volume: 77, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Anxiety; Cross-Over Studies; Depressio

2006
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Neurology, 1995, Volume: 45, Issue:11

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind

1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Neurology, 1995, Volume: 45, Issue:11

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind

1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Neurology, 1995, Volume: 45, Issue:11

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind

1995
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
    Neurology, 1995, Volume: 45, Issue:11

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind

1995
A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome.
    Annals of the New York Academy of Sciences, 1995, May-25, Volume: 753

    Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Postpoliomyelitis Syndrome; Surveys and Questionna

1995
The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.
    Archives of neurology, 1996, Volume: 53, Issue:2

    Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Attention; Central Nervous System Stimulants; C

1996
Amantadine influences cognitive processing in patients with multiple sclerosis.
    Pharmacopsychiatry, 2000, Volume: 33, Issue:1

    Topics: Adult; Amantadine; Attention; Brain; Cognition; Dopamine Agents; Double-Blind Method; Evoked Potenti

2000
Amantadine treatment of fatigue associated with multiple sclerosis.
    Archives of neurology, 1989, Volume: 46, Issue:6

    Topics: Adult; Amantadine; Circadian Rhythm; Fatigue; Female; Humans; Male; Middle Aged; Multiple Sclerosis;

1989
A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1987, Volume: 14, Issue:3

    Topics: Activities of Daily Living; Adult; Amantadine; Clinical Trials as Topic; Depression; Double-Blind Me

1987
Amantadine, fatigue, and multiple sclerosis.
    Archives of neurology, 1988, Volume: 45, Issue:10

    Topics: Amantadine; beta-Endorphin; beta-Lipotropin; Disability Evaluation; Fatigue; Humans; Lactates; Lacti

1988
Amantadine therapy for fatigue in multiple sclerosis.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1985, Volume: 12, Issue:3

    Topics: Amantadine; Clinical Trials as Topic; Fatigue; Humans; Multiple Sclerosis

1985
Quantitative evaluation of neuropharmacological trials.
    Clinical pharmacology and therapeutics, 1974, Volume: 15, Issue:3

    Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin

1974

Other Studies

18 other studies available for amantadine and Fatigue

ArticleYear
Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:14

    Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Risk Assessment

2021
Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2021, Volume: 27, Issue:14

    Topics: Amantadine; Disease Progression; Fatigue; Female; Humans; Multiple Sclerosis; Multiple Sclerosis, Ch

2021
Are drugs for multiple sclerosis fatigue just placebos?
    The Lancet. Neurology, 2021, Volume: 20, Issue:1

    Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Methylphenidate; Modafinil; Multiple Sclerosis; Ph

2021
Amantadine for COVID-19.
    Journal of clinical pharmacology, 2021, Volume: 61, Issue:3

    Topics: Amantadine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Fatigue; Humans; Multiple Sclerosis

2021
[Ehlers-Danlos and dystonia. Positive effects of amantadine].
    Presse medicale (Paris, France : 1983), 2014, Volume: 43, Issue:9

    Topics: Adult; Amantadine; Antiparkinson Agents; Craniocerebral Trauma; Dystonia; Ehlers-Danlos Syndrome; Fa

2014
Neurophysiological Correlates of Central Fatigue in Healthy Subjects and Multiple Sclerosis Patients before and after Treatment with Amantadine.
    Neural plasticity, 2015, Volume: 2015

    Topics: Adult; Amantadine; Evoked Potentials, Motor; Fatigue; Female; Fingers; Humans; Male; Middle Aged; Mo

2015
Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study.
    Acupuncture in medicine : journal of the British Medical Acupuncture Society, 2013, Volume: 31, Issue:1

    Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Amantadine; Child; Drug Resistance; Fatigue; Female; H

2013
Fatigue and depression are associated with poor quality of life in ALS.
    Neurology, 2003, Sep-23, Volume: 61, Issue:6

    Topics: Adaptation, Psychological; Amantadine; Amyotrophic Lateral Sclerosis; Caregivers; Cross-Sectional St

2003
Treating fatigue in patients with MS: one step forward, one step back.
    Neurology, 2005, Apr-12, Volume: 64, Issue:7

    Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants

2005
[Fatigue and episodic exhaustion as a feature of multiple sclerosis].
    Revue neurologique, 2006, Volume: 162, Issue:3

    Topics: 4-Aminopyridine; Amantadine; Amifampridine; Benzhydryl Compounds; Fatigue; Humans; Hypnotics and Sed

2006
Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS).
    Multiple sclerosis (Houndmills, Basingstoke, England), 2007, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Aged; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Dopami

2007
Fatigue in MS.
    Neurology, 1996, Volume: 47, Issue:5

    Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis

1996
Fatigue in MS.
    Neurology, 1996, Volume: 47, Issue:5

    Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Pemoline

1996
[Insomnia during treatment with amantadine].
    Revista de neurologia, 1997, Volume: 25, Issue:148

    Topics: Adult; Amantadine; Dopamine Agents; Fatigue; Humans; Male; Multiple Sclerosis; Sleep Initiation and

1997
[Therapeutic indications for managing symptoms: fatigue].
    Revue neurologique, 2001, Volume: 157, Issue:8-9 Pt 2

    Topics: Amantadine; Aminopyridines; Double-Blind Method; Fatigue; Humans; Multiple Sclerosis; Randomized Con

2001
Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1992, Volume: 19, Issue:2

    Topics: Adult; Amantadine; Fatigue; Female; Humans; Male; Multiple Sclerosis; Pain

1992
Amantidine, the old anti-Parkinson medication, being useful in the fatigue syndrome that often accompanies multiple sclerosis.
    South Dakota journal of medicine, 1991, Volume: 44, Issue:9

    Topics: Amantadine; Fatigue; Fatigue Syndrome, Chronic; Humans; Male; Middle Aged; Multiple Sclerosis; Parki

1991
Post-polio fatigue treated with amantadine.
    Archives of neurology, 1991, Volume: 48, Issue:6

    Topics: Amantadine; Fatigue; Humans; Postpoliomyelitis Syndrome

1991